Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Mar 28, 2025, 4:00 PM
1.245
+0.015 (1.22%)
After-hours: Mar 28, 2025, 7:53 PM EDT
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 21 employees as of December 31, 2023. The number of employees decreased by 6 or -22.22% compared to the previous year.
Employees
21
Change (1Y)
-6
Growth (1Y)
-22.22%
Revenue / Employee
$4,995
Profits / Employee
-$410,371
Market Cap
822.37K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BDRX News
- 11 days ago - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Accesswire
- 20 days ago - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP - GlobeNewsWire
- 24 days ago - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP - GlobeNewsWire
- 4 weeks ago - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewsWire
- 6 weeks ago - Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 - GlobeNewsWire
- 6 weeks ago - Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Accesswire
- 6 weeks ago - Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewsWire
- 2 months ago - Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer - GlobeNewsWire